Emerging Biomarkers for Early Detection of Metabolic Syndrome: A Comprehensive Review
IFR Journal of Biochemistry and Biomedical Science · 21.06.2026 · 2 (2) · 104-113
DOI: 10.70146/bbsv02i02.0017 ↗Kurz gefasst
Fachartikel in der Zeitschrift IFR Journal of Biochemistry and Biomedical Science, erschienen am 21.06.2026. Verfasst von Dr. Pradosh Samal und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Metabolic syndrome (MetS) refers to a complex disorder that results from the interaction of different metabolic issues including abdominal obesity, resistance to insulin, high blood pressure, abnormal cholesterol levels, and problems with glucose metabolism. The number of people affected by MetS worldwide is rising rapidly, and it is now considered a major health threat due to its strong link with heart diseases, diabetes type 2, and a higher risk of death. Usually, standard diagnostic techniques recognize the disease after major metabolic changes have already occurred. So, there is a requirement for more sensitive methods for early diagnosis.
Objective
This review was designed to thoroughly assess the available literature on the new biomarkers involved with the early detection of metabolic syndrome and to evaluate their possible clinical application in risk prediction, diagnosis, and disease monitoring.
Methods
The thorough narrative review was done based on a selection of peer-reviewed articles that studied biomarkers linked to metabolic syndrome. The papers reviewed were mainly on adipokines, inflammation mediators, biomarkers of thrombosis, and molecular markers of metabolic diseases. Information about biomarker properties, functions in organisms, correlations with metabolic risk factors, and clinical applications was collected, critically evaluated, and thoroughly synthesized.
Results
The study results revealed various new biomarkers: adiponectin leptin resistin, plasminogen activator inhibitor-1 (PAI-1), high-sensitivity C-reactive protein (hs-CRP), gamma-glutamyl transferase (GGT), and microRNA-related pathways that are Really connected with obesity, insulin resistance, inflammation, and other cardiometabolic issues. Metabolically risky factors tend to be inversely linked with adiponectin But leptin and other inflammatory and thrombotic factors are markedly higher in those with metabolic abnormalities. The use of multiple biomarkers together in the form of panels markedly increases the accuracy in detecting individuals at risk than relying on individual biomarkers. Besides that, the changes for the better in the levels of biomarkers were observed by way of the application of therapeutic interventions such as lifestyle modifications and exercise-based methods.
Conclusion
Emerging biomarkers uncover significant details about the fundamental mechanisms of metabolic syndrome as well as show promising potential for more timely identification of individuals who are at risk. Integrating various biomarkers into prediction models could enhance the precision of diagnosis and help in crafting personalized prevention and treatment plans More big studies are needed to validate the use of biomarkers and to make it possible for them to be regularly used in clinical practice.
Zitieren
APA
Samal, D. P., Jayantibhai, D. S. J., & Nayak, D. S. (2026). Emerging Biomarkers for Early Detection of Metabolic Syndrome: A Comprehensive Review. IFR Journal of Biochemistry and Biomedical Science, 2(2), 104-113. https://doi.org/10.70146/bbsv02i02.0017
Vancouver
Samal DP, Jayantibhai DSJ, Nayak DS. Emerging Biomarkers for Early Detection of Metabolic Syndrome: A Comprehensive Review. IFR Journal of Biochemistry and Biomedical Science. 2026;2(2):104-113. doi:10.70146/bbsv02i02.0017
BibTeX
@article{Samal2026,
author = {Samal, Dr. Pradosh and Jayantibhai, Dr. Suhagiya Jinay and Nayak, Dr. Sanjeeta},
title = {Emerging Biomarkers for Early Detection of Metabolic Syndrome: A Comprehensive Review},
journal = {IFR Journal of Biochemistry and Biomedical Science},
year = {2026},
volume = {2},
number = {2},
pages = {104--113},
doi = {10.70146/bbsv02i02.0017}
}
EUVIMED